A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
Solid Tumors, Adult
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 147 (planned)
- Started
- Dec 16, 2025
- Main results expected
- Nov 30, 2028
- Fully finished
- Dec 31, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Maximum Tolerated Dose (MTD)
Measured over: Approximately 12 months
Recommended doses for expansion (RDE)
Measured over: Approximately 12 months
Overview of Treatment-emergent Adverse Events (TEAEs)
Measured over: Approximately 24 months
Objective Response Rate (ORR)
Measured over: At least 6 weeks post dose of first participant up to approximately 24 months
Recommended doses for phase II or III studies (RP2D or RP3D) of HMPL-A251
Measured over: Approximately 12 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07228247 · record last updated 2026-09-22 · checked 2026-11-09 15:36 UTC